Today Su

C.E.O.
Golden Biotechnology Corp.
 

Dr. Su is an experienced scientist and businessman worked for major challenges in Taiwan’s biotech industry for over two decades. He started in a biologic therapeutic vaccine company then later on a genomics company – two major areas gotten high attention from Taiwan. He then shifted to a venture capital firm for first hand buy-side experiences about the financing dynamics in related industries. Subsequently, he joined a medical device company for cancer treatment and then returned to vaccine sector as the CSO and was tasked to bring their product to the European market. After conducting the largest trail with 2000 subjects, the TW company got access to market, and he gained valuable professional experience. His challenge and priority now at GBC is to establish sizeable licensing partnership with a global company. Currently, GBC's drug development, even in the long-term indications, has a short outlook and continue trials long term in areas with high unmet need like orphan drug market.
 

Speech title & Synopsis

Acquiring Triple A Resilience with Antroquinonol

COVID-19 pandemic is not only a health crisis but also an inescapable restructuring of the old standard value. Although pioneering therapeutics such as mRNA-based vaccines fights SARS-CoV-2, therapeutic challenges have emerged due to the increased SARS-CoV-2 variants and the lack of safe and effective medicines simultaneously targeting distinct phases of COVID-19. Responding to the pandemic management after vaccination, Golden Biotech will provide a high level of Adaptability to fit fast-changing circumstances, easy Accessibility and Affordability of safe and effective medicines.
 
Golden Biotech has a phase II clinical trial of Antroquinonol for fighting COVID-19 pandemic. This phase II trial is a randomized, double blind and placebo controlled study to evaluate the safety and efficacy of Antroquinonol in mild-moderate COVID-19 hospitalized patients. Initial and interim results received a positive response from the Data Monitoring Committee (DMC), an independent group approved by the U.S. FDA, which also suggested that the Antroquinonol study be expanded to severe COVID-19 hospitalized patients on non-invasive ventilation or high-flow oxygen. Antroquinonol exhibited anti-viral, anti-inflammatory and anti-fibrotic characteristics in previous preclinical studies, which suggests effective abilities to treat patients at distinct phases of COVID-19. Based on previous clinical studies, demonstrated safety profile with low risks of adverse effects, and high efficacy carrying additional side benefits make Antroquinonol a safe medicine. Additionally, oral Antroquinonol formulation can fight COVID-19 early and enable the widespread.
 
Navigating to effective pandemic management after vaccination, Golden Biotech contributes to the global effort to relieve the burden of COVID-19 pandemic. Future development in making Antroquinonol a new formulation, such as nasal spray or inhalation, is being planned to protect an individual or prevent further spread of SARS-CoV-2. Economical and scalable synthesis of Antroquinonol currently enables a wider range of affordable real-world applications. Together, Golden Biotech will provide the triple A Antroquinonol in the post-vaccination era.